

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising at least about one hundred CD34<sup>+</sup> cells within a plurality of potent cells, the unit comprising cells from a plurality of sources, wherein said plurality of potent cells comprises ~~CD34<sup>-</sup>OCT-4<sup>+</sup>~~ CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells that have been isolated from postpartum placenta perfusate.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Previously presented) The cytotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood or fetal tissue.
6. (Previously presented) The cytotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood.
7. (Canceled)
8. (Previously presented) The cytotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from postpartum placenta.
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Previously presented) The cytotherapeutic unit of claim 1 wherein said potent cells are obtained from at least two individuals.
13. (Previously presented) The cytotherapeutic unit of claim 1 wherein said potent cells are obtained from at least five individuals.
14. (Canceled)
15. (Original) The cytotherapeutic unit of claim 1 wherein at least one type of cell is excluded from the unit.
16. (Original) The cytotherapeutic unit of claim 1 wherein the plurality of potent cells is selected to render the cytotherapeutic unit suitable for therapy for an indicated disease state or condition.
17. (Original) The cytotherapeutic unit of claim 16 wherein at least one type of cell is excluded from the unit.

18. (Currently amended) A cytotherapeutic unit suitable for the treatment of a patient in need of hematopoietic cells comprising at least two preselected types of potent cells, said unit comprising cells from a plurality of sources, wherein said potent cells comprise ~~CD34<sup>-</sup>OCT-4<sup>+</sup>~~ CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells that have been isolated from postpartum placenta perfusate, and wherein at least about one hundred of said potent cells are CD34<sup>+</sup>.

19. (Canceled)

20. (Previously presented) The cytotherapeutic unit of claim 18, distributed with a certification of the contents of said cytotherapeutic unit.

21. (Previously presented) The cytotherapeutic unit of claim 20 wherein said certification comprises an indication of cells excluded from said cytotherapeutic unit.

22. (Previously presented) The cytotherapeutic unit of claim 20 wherein said certification comprises an indication of cells absent from said cytotherapeutic unit.

23. (Previously presented) The cytotherapeutic unit of claim 20, wherein said certification indicates how the presence, absence, and/or exclusion of certain cell types render or renders the cytotherapeutic unit suitable for therapy for an indicated disease state or condition.

24.-30.(Canceled)

31. (Currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising (a) cells obtained from umbilical cord blood and (b) ~~CD34<sup>-</sup>OCT-4<sup>+</sup>~~ CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells isolated from postpartum placenta perfusate, wherein at least one type of cell has been removed from the unit, and wherein at least about one hundred cells remaining in the unit are CD34<sup>+</sup>.

32. (Previously presented) The cytotherapeutic unit of claim 31 wherein a plurality of cell types has been removed from the unit.

33. (Canceled)

34. (Currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising a mixture of cells obtained from umbilical cord blood and ~~CD34<sup>-</sup>OCT-4<sup>+</sup>~~ CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells isolated from postpartum placenta perfusate, said cells comprising a plurality of different types, at least one of the different types having been obtained from a source that differs from a source of another type and wherein at least about one hundred cells are CD34<sup>+</sup>.

35. (Previously presented) The cytotherapeutic unit of claim 34, wherein at least one of said types of cells has been frozen separately from another type of cells.

36. (Original) The cytotherapeutic unit of claim 34, in a frozen state.

37. (Previously presented) The cytotherapeutic unit of claim 34, wherein at least one of said cells has been characterized.

38.-49.(Canceled)

50. (Currently amended) A library of cytotherapeutic units suitable for treatment of a patient in need of hematopoietic cells, each unit member of said library comprising a plurality of potent cells; each of said units comprising cells from a plurality of sources, wherein said plurality of potent cells in each of said unit members of said library comprises ~~CD34<sup>-</sup>OCT-4<sup>+</sup>~~ CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells that have been isolated from postpartum placenta perfusate; each of said units being assayed to ensure accuracy of identities and numbers of at least some of the plurality of potent cells comprising said unit, and each of said units comprising at least about one hundred CD34<sup>+</sup> cells.

51.-53. (Canceled)

54. (New) The cytotherapeutic unit of claim 1, wherein said CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells are additionally CD10<sup>+</sup>, CD29<sup>+</sup>, CD38<sup>-</sup>, CD44<sup>+</sup>, CD45<sup>-</sup>, CD54<sup>+</sup>, CD90<sup>+</sup>, SH2<sup>+</sup>, SH3<sup>+</sup>, SH4<sup>+</sup>, SSEA4<sup>-</sup>, and ABC-p<sup>+</sup>.

55. (New) The cytotherapeutic unit of claim 18, wherein said cells that are CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells are additionally CD10<sup>+</sup>, CD29<sup>+</sup>, CD38<sup>-</sup>, CD44<sup>+</sup>, CD45<sup>-</sup>, CD54<sup>+</sup>, CD90<sup>+</sup>, SH2<sup>+</sup>, SH3<sup>+</sup>, SH4<sup>+</sup>, SSEA4<sup>-</sup>, and ABC-p<sup>+</sup>.

56. (New) The cytotherapeutic unit of claim 31, wherein said cells that are CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells are additionally CD10<sup>+</sup>, CD29<sup>+</sup>, CD38<sup>-</sup>, CD44<sup>+</sup>, CD45<sup>-</sup>, CD54<sup>+</sup>, CD90<sup>+</sup>, SH2<sup>+</sup>, SH3<sup>+</sup>, SH4<sup>+</sup>, SSEA4<sup>-</sup>, and ABC-p<sup>+</sup>.

57. (New) The cytotherapeutic unit of claim 34, wherein said cells that are CD34<sup>-</sup>, OCT-4<sup>+</sup> and SSEA3<sup>-</sup> cells are additionally CD10<sup>+</sup>, CD29<sup>+</sup>, CD38<sup>-</sup>, CD44<sup>+</sup>, CD45<sup>-</sup>, CD54<sup>+</sup>, CD90<sup>+</sup>, SH2<sup>+</sup>, SH3<sup>+</sup>, SH4<sup>+</sup>, SSEA4<sup>-</sup>, and ABC-p<sup>+</sup>.